DL-TBOA ammonium is a potent non-transportable inhibitor of excitatory amino acid transporters with IC 50 s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1) , EAAT2 and EAAT3 , respectively. DL-TBOA ammonium inhibits the uptake of [ 14 C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with K i valuesof 42 μM and 5.7 μM, respectively. DL-TBOA ammonium blocks EAAT4 and EAAT5 in a competitive manner with K i values of 4.4 μM and 3.2 μM, respectively.

DL-TBOA ammonium (70-350 μM; 48 hours) treatment concentration-dependently enhances SN38-induced loss of viability. DL-TBOA reversed Oxaliplatin-induced loss of viability[4]. DL-TBOA ammonium (350 μM; 24 hours) decreases p53 induction by SN38 and oxaliplatin[4]. Cell Viability Assay[4]Cell Line: HCT116 cells, LoVo cells Concentration: 70 μM, 350 μM Incubation Time: 48 hours Result: Enhanced SN38-induced, and counteracted Oxaliplatin-induced, cell death. Cell Viability Assay[4]Cell Line: HCT116 cells, LoVo cells Concentration: 350 μM Incubation Time: 24 hours Result: Decreased p53 induction by SN38 and oxaliplatin.

DL-TBOA ammonium (10 nmol; i.c.v.) to morphine-dependent rats significantly facilitates the expression of naloxone-precipitated somatic signs and conditioned place aversion[5]. Animal Model: Male Sprague-Dawley rats (180-250 g)[5]Dosage: 1 nmol, 3 nmol, 10 nmol Administration: Intracerebroventricularly injection (i.c.v.) Result: Dose dependently facilitated various somatic signs induced by Naloxone (0.1 mg/kg)-precipitated morphine withdrawal.

2093503-71-8

C11H16N2O5

256.258

DL-TBOA ammonium

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years